Osteoporosis drugs compared for side effects, efficacy in Loyola study
(Loyola University Health System) A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 2, 2013 Category: Global & Universal Source Type: news
Risk of osteoporosis drug's side effects not significant, Loyola researchers find
(Loyola University Health System) The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System. These findings were presented earlier this month at the American Society for Bone and Mineral Research's annual meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 30, 2013 Category: Global & Universal Source Type: news
Big Pharma’s plan to poison your bones
Would you use a drug that poisons a part of your body? That’s what the medical community is doing to your bones when you take bone drugs. Fosamax, Actonel, Boniva, Reclast, Zometa, Didronel, Aredia, Skelid… they’re all the same. Taking them is like feeding poison to the cells your body uses to remodel bone. Why [...]Related Posts:This mineral mends your DNABetter Than Aspirin (Source: Al Sears, MD Natural Remedies)
Source: Al Sears, MD Natural Remedies - October 28, 2013 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging Heart Health Nutrition supplements vitamins Source Type: news
Sagent Pharmaceuticals Announces the Launch of Zoledronic Acid Injection 5 mg in a Premix Bag
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - October 14, 2013 Category: Pharmaceuticals Source Type: news
Once-a-Year Zoledronic Acid Preserves Bone in Elderly, FrailOnce-a-Year Zoledronic Acid Preserves Bone in Elderly, Frail
An annual injection shows benefits with regard to bone-mineral density in the population most at risk. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Exposure to Reclast: Risks for Implant Treatment?
Would the one time exposure to Reclast over 2 years ago still have any influence on her bone healing and risk of BRONJ? (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 27, 2013 Category: Dentistry Authors: osseonews Tags: Dental Implants Q&A Source Type: news
Osteonecrosis of the Jaw Linked to Adjuvant Zoledronic AcidOsteonecrosis of the Jaw Linked to Adjuvant Zoledronic Acid
Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Zoledronic Acid Slows Bone Loss, Also Stops New Bone Formation
The commonly used osteoporosis drug zoledronic acid slows bone loss in postmenopausal osteoporosis patients, but it also boosts levels of a biomarker that inhibits bone formation, according to a study recently published online edition in the Journal of Clinical Endocrinology & Metabolism (Source: AAFP Health of the Public)
Source: AAFP Health of the Public - April 24, 2013 Category: Primary Care Source Type: news
Zoledronic, A Common Osteoporosis Drug Slows Formation Of New Bone
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Osteoporosis weakens bones and increases the risk patients will suffer fractures. The findings suggest combination therapy may be a more effective approach to battling this common condition... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 19, 2013 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news
Common osteoporosis drug slows formation of new bone (EurekAlert, 17 April 2013)
A study from Italy published in Journal of Clinical Endocrinology & Metabolism assesses sclerostin levels as a measure of bone formation in women treated with zoledronic acid.
Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 18, 2013 Category: Endocrinology Source Type: news
Zoledronic Acid Did Not Prevent Bone Metastases in High-Risk Prostate Cancer
The use of zoledronic acid (Zometa) had no effect on the prevention of bone metastases in patients with high-risk prostate cancer, according to the first results of the Zometa European Study, or ZEUS, presented at the European Association of Urology 28th Annual Congress in Milan, Italy. (Source: Cancer Network)
Source: Cancer Network - April 18, 2013 Category: Cancer & Oncology Source Type: news
Common osteoporosis drug slows formation of new bone
(The Endocrine Society) Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 17, 2013 Category: Global & Universal Source Type: news
Zoledronic Acid Fails to Halt Metastasis in Prostate CancerZoledronic Acid Fails to Halt Metastasis in Prostate Cancer
This bisphosphonate shows no benefit over standard options, according to the first results from the Zometa European Study, or ZEUS. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2013 Category: Consumer Health News Tags: Urology News Source Type: news
In High-Risk Prostate Cancer, Zoledronic Acid Not Found To Prevent Bone Metastases
The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic prostate cancer patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 21, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Zoledronic acid does not prevent bone metastases in high-risk PCa patients
(European Association of Urology) The initial study results of the Zometa European Study showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Professor Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress, which ends today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 19, 2013 Category: Global & Universal Source Type: news
